Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2 E1.3 - Challenges and Big Ideas for NAFLD/NASH Patient Diagnosis and Treatment in the Post-Second Wave World
Question: If NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening?
This conversation asks a two-part question: How do we motivate primary care treaters and specialists who treat metabolic syndromes to manage NAFLD more aggressively? The conversation considers education and telemedicine in this context and then turns to two very ambitious concepts. One of these deals with screening, the other with treatment before approvals. Listen until the end then let us know what you think and what big ideas you, yourself might have.